People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
Eligible age
18–70 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest. For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hole peg test, and SDMT score.
Sponsor: Northwestern University
You may qualify if…
- ✓ Diagnosis of MS (2019 revised McDonald criteria) of any type (PPMS, RRMS, SPMS) by a neurologist,
- ✓ Adult age 18-70 years,
- ✓ BMI \>=24.0 kg/m2,
- ✓ Taken at least one dose of Ocrelizumab prior to study entry,
- ✓ EDSS \<7.0,
- ✓ Able to provide individual informed consent,
- ✓ MRI available to confirm the diagnosis of MS.
You may not qualify if…
- ✕ Prior exposure to Mavenclad, Lemtrada, Cyclophosphamide, stem cell transplant or related bone marrow suppressive treatment,
- ✕ Current clinical trial participant,
- ✕ Unable to speak a language for which translation can be found in the hospital system,
- ✕ Unclear documentation of MS diagnosis or prior or current MS treatment,
- ✕ Relapse within the past 3 months,
- ✕ Recent major surgical procedure in the past 6 months,
- ✕ Exposure to steroids (systemic) within the past 3 months,
- ✕ Not on Ocrelizumab in the past \>9 months,
Where it's recruiting
Chicago
Source: ClinicalTrials.gov · NCT07207148 · last updated 2026-03-17